Resmed delivered a strong quarterly result with record revenue and income for the period
Resmed delivered a strong quarterly result with record revenue and income for the period. Revenue was $397.8million, a 4% increase over the quarter ended March 31, 2013. Net income was $90.0 million an increase of 6% compared to the quarter ended March 31, 2013. In our most recent Buy Hold Sell episode Roger Montgomery, CIO of Montgomery Investment Management, and Don Williams, CIO of Platypus Asset Management, both share their views on Resmed (amongst other healthcare stocks). Both Fund managers rate Resmed as a Buy, citing that the business is coming out of a tough period and growth in the treatment of sleep apnea has plenty of room to go. Earlier this week Livewire contributor Michael Gable also suggested Resmed is now in Buy territory, currently trading at $5.10 Gable sees a long term target of $6. Video here:
& Michael's wire here: (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Livewire is Australia’s #1 website for expert investment analysis. We work with leading investment professionals to deliver curated content that helps investors make confident and informed decisions.
Safe investing and thanks for reading Livewire.
2 topics
Livewire is Australia’s #1 website for expert investment analysis. We work with leading investment professionals to deliver curated content that helps investors make confident and informed decisions. Safe investing and thanks for reading Livewire.
Expertise
Livewire is Australia’s #1 website for expert investment analysis. We work with leading investment professionals to deliver curated content that helps investors make confident and informed decisions. Safe investing and thanks for reading Livewire.
Expertise
Comments
Comments
Sign In or Join Free to comment